The elucidation of gastric inhibitory polypeptide-dependent Cushing's syndrome suggested that ectopic expression or increased responsiveness of other adrenal hormone receptors may underlie ACTH-independent macronodular adrenal hyperplasia (AIMAH) or adrenocortical tumors. We studied a 36-yr-old woman with Cushing's syndrome, AIMAH, and orthostatic hypotension. During upright posture, cortisol and aldosterone were stimulated despite suppression of ACTH and renin. Arginine vasopressin (AVP, 10 U im), under dexamethasone suppression, increased plasma cortisol (3.4-fold), aldosterone (67-fold), and androgens in this patient but not in controls. ACTH 1-24, but not desmopressin acetate, angiotensin II, isoproterenol, or other hormones stimulated steroidogenesis in vivo. Plasma AVP was undetectable initially and increased suboptimally during posture tests after bilateral adrenalectomy. AVP stimulated cortisol production more in dispersed cells from the AIMAH than from a normal adult adrenal (424 vs. 135% at 10 nmol/L). Adrenal V 1 -AVP receptor presence and mediation of response were shown by RT-PCR and by binding and [Ca ϩϩ ] i studies. Post adrenalectomy, orthostatic hypotension persisted; a prolonged vasoconstrictive response to AVP was found in vitro in the patient's sc small arteries. We propose that altered adrenal and vascular responses of the V 1 -AVP receptor-effector pathway underlie this new syndrome. (J Clin Endocrinol Metab 82: 2414 -2422, 1997) A CTH-INDEPENDENT Cushing's syndrome usually is secondary to unilateral adrenal adenomas or carcinomas and rarely to bilateral adrenal hyperplasia (1, 2). Primary pigmented nodular adrenocortical disease can be familial and associated with several other tumors in the Carney complex and to an unknown chromosome 2 gene (3). In McCune-Albright syndrome, activating mutations of protein G s ␣ in adrenal nodules results in a constitutive stimulation of steroidogenesis (4). Recently, we (5) and others (6, 7) described food-dependent cortisol production in three women with ACTH-independent macronodular bilateral adrenal hyperplasia (AIMAH) and in one man (8) and one woman (9) with adrenal adenomas; this syndrome was secondary to an ectopic expression or increased responsiveness of gastric inhibitory polypeptide receptors in the adrenals.
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These findings raised the hypothesis that adrenal proliferation and function in adrenocortical hyperplasia or tumors may be secondary to abnormalities of receptors for various other hormones or growth factors. We now describe a patient with Cushing's syndrome in whom steroid production from AIMAH was stimulated by upright posture and administration of arginine vasopressin (AVP); in addition, orthostatic hypotension and abnormal vascular response to AVP was present in the same patient.
referral. Weight decreased from 67 to 50 kg, but fatigue and dizzy spell episodes persisted at a reduced severity. Urinary cortisol normalized, but ACTH levels remained undetectable. Ketoconazole was discontinued 1 week before investigation.
Blood pressure was 120/70 mm Hg, sitting, weight was 48 kg, and height was 160 cm; there were no residual signs of hypercorticism. Pituitary magnetic resonance imaging was normal. After investigation, bilateral adrenalectomy was performed; the left adrenal measured 9 ϫ 4 ϫ 2 cm (36 g), and the right adrenal measured 6.5 ϫ 3 ϫ 1.5 cm (17 g ). Both adrenals were diffusely enlarged with alternance of clear and acidophilic micronodules, without internodular atrophy.
The patient was treated with hydrocortisone (30 mg) and fludrocortisone (0.1 mg) daily. During the following 6 months, weight was stable, but symptomatic orthostatic hypotension persisted. Support stockings and an increase of fludrocortisone to 0.15 mg daily did not improve symptoms. After reevaluation 7 months post adrenalectomy, treatment with an ␣-adrenergic agonist, midodrine chlorhydrate (Amatine, Boots Pharmaceuticals, Eobicoke, Ont; 5 mg orally three times daily), partially improved the control of blood pressure and of symptoms.
Methods
Clinical studies. Pituitary adrenal function was studied in the patient with AIMAH, in seven normal control individuals, and in one woman each with either an adrenal pheochromocytoma or normal pituitary-adrenal function 2 yr after removal of a corticotroph pituitary adenoma or with mild cyclic Cushing's disease. The study protocols were approved by the institutional review committee, and written informed consent was obtained from all subjects.
Studies were performed, after an overnight fast, in the supine position for 60 min before testing. The protocol included serial measurements at 30 -60 min intervals of plasma ACTH, cortisol, aldosterone, free testosterone, dehydroepiandrosterone sulfate, and estradiol during the course of the various tests. On the first day, a combined stimulation with luteinizing hormone release hormone (LHRH) (100 g; Factrel, WyethAyerst, Montréal, Québec, Canada), TRH (200 g; Relefact, HoechstRoussel, Montréal, Québec), GHRH 1-27 (1.2 g/kg; Ferring Inc., North York, Ontario, Canada) iv bolus was performed; this was followed, 180 min later, by a stimulation test with 250 g iv ACTH 1-24 (Cortrosyn, Organon Canada Ltd, Scarborough, Ontario). On the second day, a posture test was performed in a 2-h supine position, followed by a 2-h ambulation period. One hour later, a mixed meal was administered; this was followed, 2 h later, by stimulation with 1 g/kg iv ovine CRH (ACTHREL, Ferring Inc). On the third day, stimulation with 10 U im AVP (Pitressin, Parke-Davis, Scarborough, Ontario) was performed, followed, 120 min later, by an insulin-induced hypoglycemia (0.15 U/kg). On the subsequent day, glucagon (Eli Lily Canada Inc. Scarborough, Ontario) 1 mg was injected iv, and this was followed 120 min later by an iv dexamethasone test (1 mg/h from 1100 h to 1500 h), as described previously (5); however, in this study, AVP (10 U) was injected im at 1400 h. A desmopressin stimulation was performed by sc injection of 2.5 g desmopressin acetate (dDAVP) (Ferring Inc). Angiotensin II (Hypertensin, Ciba-Geigy, Mississauga, Ontario)) was infused at a rate of 1 ng/kg⅐min during 15 min, and at 3 ng/kg⅐min during 30 min, to increase blood pressure by 30/15 mm Hg; isoproterenol (Isuprel Sanofi Winthrop, Markham, Ontario) was injected as a 1-g iv bolus and increased heart rate by 54 beats/min. ACTH 1-24 sensitivity test was performed by sequential injections of 0.1, 1.0, and 5 g Cortrosyn at 2-h intervals. In vitro studies with dispersed adrenal cells. Portions of both adrenal glands were dispersed and incubated (1 ϫ 10 6 cells/mL) in DMEM (Gibco Canada, Mississauga, Ontario), without serum, with various hormones during 2 h at 37 C, as described previously (5); after incubation, medium was collected and frozen at Ϫ20 C for assay of cortisol concentration.
Assays. Plasma, urinary, and cell media concentrations of cortisol were measured by a commercial RIA kit (Quanticoat Kallestad Diagnostics, Chaska, MN), as were other steroids, renin, and ACTH (IRMA Allegro, Nichols Diagnostics, San Juan Capistrano, CA). Plasma AVP RIA was performed, as described previously (10), with an assay sensitivity of 0.1 pg/assay tube and a limit of detection in plasma of 0.25 pg/mL. RIA for atrial natriuretic peptide (ANP) and for ET-l levels were performed as described previously (11, 12) .
Measurement of calcium in isolated cells. Cells, plated at a density of 10 6 cells/well and grown for 3 days on glass coverslips, were washed three times with 2 mL modified HBSS; cells were loaded with Fura-2, AM (4 mol/L) in dimethyl sulfoxide with 0.02% pluronic acid, and incubated for 30 min at 37 C in a humidified incubator (95% air-5% CO 2 ). Cells were then washed three times and [Ca 2ϩ ] i was measured in multiple cells simultaneously by fluorescent digital imaging using the Attofluor Digital Fluorescence System (Axiovert 135 inverted microscope, Zeiss, West Germany), as described previously (13) . Dose response curves for ET-1 (14) . Binding was stopped by 3 mL ice cold DMEM, followed by rapid filtration through glass fibre filters no. 34 (Schleicher & Schuell, Keene, NH), and counting the radioactivity in washed filters in a Rackgamma ␤ LKB counter with 40% efficiency.
RT-PCR of vasopressin receptors.
Total RNA was extracted by the guanidium thiocyanate/cesium chloride method. Two g RNA were reverse transcribed with random hexamers. Three sets of specific oligodeoxynucleotides for the vasopressin receptors V 1 , V 2 , and V 3 were provided by Dr, Yves de Keyzer, Institut Cochin de Génétique Molécu-laire, Paris, and are described elsewhere (15) . PCR was performed in 20 mmol/L Tris-HCl (pH 8.4), 50 mmol/L KCl, 2 mmol/L MgCl 2 , and 0.5 mmol/L dNTP with 25 pmol/L of each primer. After 35 cycles (45 sec at 94 C, 45 sec at 58 -62 C, 1 min at 72 C), 10% of the reaction was analyzed on a 3% agarose gel, and the bands were revealed by ethidium bromide staining.
In vitro stimulation of small sc arteries. A biopsy of gluteal sc fat was obtained; small arteries (ϳ250 m lumen diameter) were mounted on a wire myograph and stimulated sequentially with norepinephrine (0.01-10 mol/L), AVP (0.01-30 nmol/L), angiotensin II (0.1-300 nmol/ L), and ET-1 (0.01-1 mol/L), as described previously (16) .
Statistical analysis.
Comparison of mean values was performed by ANOVA, followed by Bonferroni's correction for multiple testing. Concentration-response curves were fitted by nonlinear regression using the Instat and Inplot programs (Graphpad Software, San Diego, CA), and the EC 50 (concentration giving 50% of the maximum response) was determined and the pD 2 calculated as -log [EC 50 (mol/L)]. Receptor affinity and density were estimated by computer analysis using the nonlinear regression, curve-fitting program LIGAND.
Results

Initial in vivo studies
Plasma cortisol varied between 271-543 nmol/L fasting, without diurnal variations, whereas ACTH was less than 0.2 pmol/L; urinary free cortisol levels remained between 121-265 nmol/day on days without stimulation tests (normals: 90 -330). Various tests, including a mixed meal, insulin-induced hypoglycemia, TRH-LHRH-GHRH, or glucagon did not modify plasma cortisol (Fig. 1) or ACTH, despite appropriate fluctuations of glucose, TSH, PRL, FSH, LH, or GH (not shown). CRH administration provoked a subnormal increase of ACTH (Ͻ0.2-0.95 pmol/L) and cortisolemia (287-466 nmol/L) within 30 min. Administration of 10 U of AVP im increased plasma cortisol rapidly ( Fig. 1 ) from 501 to 1445 nmol/L, ACTH from less than 0.2 to 0.87 pmol/L, and 24-h urinary-free cortisol up to 995 nmol/day; this was associated with abdominal cramping, an increase in blood pressure (mm Hg) from 105/70 to 125/80 at 30 min, and 132/90 at 120 min, and a heart rate of 80 beats/min basally, of 64 at 30 min, and of 76 at 120 min. Administration of dDAVP did not result in any stimulation of cortisol (Fig. 1) . After an iv dexamethasone test, cortisolemia was not suppressed in the AIMAH patient (Fig. 2) , whereas in normal individuals, it suppressed to less than 51 nmol/L (35 Ϯ 11 nmol/L) at the 0900 h time point on the second day (9D2). Administration of vasopressin under dexamethasone infusion reproduced the brisk increase of cortisol in plasma (337%) and urine (1281 nmol/ day) in the AIMAH patient despite undetectable ACTH; an important stimulation of aldosterone (67-fold) and other steroids was also induced by AVP (Table 1 ). In contrast, AVP Results are expressed as percent of the cortisol value at the basal zero time point. The dashed line indicates the 100% (no effect) value.
FIG. 2.
In vivo combined iv dexamethasone-vasopressin test. Plasma cortisol levels were measured at the indicated time points, after the iv infusion of dexamethasone at 1 mg/h from 11-15 h. Patients were supine, fasted until the 16-h time point, and ate meals at 1600 h and 1830 h; posture was not standardized after 1600 h, but the patient with AIMAH (ç) was ambulating or sitting until 2200 h, was supine until 2330 h, and was upright at the 2400-h time point. Other patients were a woman with a pheochromocytoma (f), a woman with normal pituitary adrenal function 2 yr after removal of a pituitary ACTHsecreting adenoma (å), and a woman with mild cyclic Cushing's disease (F); the shaded area indicates the range of cortisol values in seven normal individuals during the iv dexamethasone test, performed without the vasopressin stimulation. 9D2 and 9D3: 0900 h on days 2 and 3, after dexamethasone infusion.
administration under dexamethasone infusion did not increase plasma cortisol levels in control patients with normal hypothalamic-pituitary-adrenal axis or Cushing's disease (Fig. 2) .
Three posture tests conducted in the patient with AIMAH produced a delayed (30 -120 min) fall of systolic blood pressure of 30 mm Hg in each test; of diastolic blood pressure of 0, 8, and 10 mm Hg; and an increase of heart rate of 36, 48, and 36 beats/min, respectively, when the patient assumed an upright posture during 120 min. Blood volume measured in upright posture showed a small decrease in total vol at 2.846 L (predicted: 3.114 L), in red cell mass at 0.928 L (predicted: 1.245 L), whereas plasma vol was normal at 1.918 L (predicted: 1.868 L). Assuming a supine posture resulted in a 27 and 35% decline in cortisol levels; an upright posture, during 2 h, resulted in a 43 and 81% peak increase in cortisol levels compared with the supine levels (ACTH undetectable). During a third test, after 2 h of supine posture, water loading with 20 mL/kg decreased cortisol levels a further 24%; however, this did not prevent orthostatic hypotension or cortisol increase during ambulation (Table 1) ; plasma AVP levels were below the limit of detection during these posture tests, whereas natremia and osmolarity remained normal. The cortisol response to orthostasis was not suppressed by dexamethasone infusion (Fig. 1) . Basal supine renin levels were relatively suppressed and did not increase during orthostatic hypotension (Table 2) ; supine aldosterone levels were in the low-to-normal range, but increased 5-to 6-fold during orthostasis despite decreased renin response. Plasma ANP decreased normally from supine to upright posture (14.5 to 6.6 nmol/L); plasma norepinephrine levels increased normally from 0.16 to 0.91 ng/mL during orthostatic hypotension. Supine plasma ET levels were in the normal range at 2.1 pmol/L but failed to increase above 2.4 pmol/L during the postural hypotension.
Infusion of angiotensin II increased blood pressure by 22/19 mm Hg, increased aldosterone levels by 69%, but did not modify plasma cortisol levels (Fig. 1 ). An iv bolus of 1 g isoproterenol increased heart rate 54 beats/min but not plasma cortisol levels (Fig. 1) . The peak cortisol increase, after ACTH 1-24 stimulation in the patient with AIMAH, was 31% with 0.1 g, 93% with 1 g, 90% with 5 g, and 314% with 250 g dose; this was not different from the response of two other patients with bilateral macronodular adrenal hyperplasia without Cushing's syndrome (not shown).
In vitro studies
Cortisol production by freshly dispersed cells from the macronodular adrenals and from normal adult human adrenal. AVP treatment stimulated cortisol production in a dose-dependent a Water load of 20 mL/kg: D 5%/water 500 mL iv and water 500 mL orally in 45 min. (Fig. 3) ; in normal adult human adrenal cells, AVP produced only a slight, nondose-dependent stimulation (135%). The AVP response was partially inhibited by the V 1 -AVPR antagonist, whereas dDAVP had no effect. ACTH 1-24 induced the largest dose-dependent increase of cortisol secretion in cells from the patient with AIMAH (913%) and from the normal adult adrenal (286%). 
Vasopressin receptor studies. Specific binding sites for
AIMAH adrenal cell Ca
ϩϩ concentrations in response to hormone treatment. Intracellular [Ca ϩϩ ] was stimulated by AVP, and this was inhibited completely by the V 1 -AVPR antagonist, whereas dDAVP had no effect (Fig. 4) 
In vivo and in vitro studies post adrenalectomy
Blood pressure regulation. The patient was reevaluated 7 months post adrenalectomy under replacement with hydrocortisone (10 mg orally) twice daily; and fludrocortisone (0.1 mg orally) daily; urinary free cortisol was normal at 238 nmol/day, with normal serum electrolyte levels. Orthostatic hypotension persisted, but plasma levels of AVP, ACTH, and renin now were detectable basally; and AVP and renin increased, albeit subnormally, during upright posture (Table  3 ). Blood vols measured after 2 h of recumbency were (L): total: 3.33; red cell mass: 1.22; plasma vol: 2.11 (normals for height and weight: 3.16, 1.26, 1.89, respectively). After 2 h of ambulation without support stockings, they were decreased to total: 2.52; red cell mass: 0.88; plasma vol: 1.64. Plasma ET levels were normal supine, but failed to increase despite hypotension. (Fig. 5) , whereas relaxation required only 5 Ϯ 1 min in this and previously published controls (16) .
In vitro small artery responses.
Discussion
This patient presented ACTH-independent Cushing's syndrome initially; control of hypercorticism by ketoconazole resulted in a subnormal recovery of ACTH response to CRH and AVP administration. However, cortisol nonsuppressibility by dexamethasone indicated that cortisol production was mostly ACTH-independent. Adrenal hyperresponsiveness to ACTH was not the mechanism of increased steroidogenesis in this patient.
We identified cortisol regulation by posture and by exogenous AVP in this patient. AVP increases cortisol production in normal subjects, by stimulating ACTH secretion directly and by potentiating CRH effects (1) . In contrast, a direct effect of AVP on adrenal steroidogenesis was demonstrated in vivo and in vitro in this AIMAH patient. Adrenal response in vivo to lysine-vasopressin were reported in canine (17) or human Cushing's syndrome from adenoma (15), or macronodular adrenal hyperplasia (18); these reports did not indicate whether posture or endogenous AVP modulated cortisol production and whether blood pressure regulation was altered.
Actions of AVP are mediated by three G protein-coupled receptors: V 1 (or V 1a ) receptor (19) expressed mainly in vascular smooth muscle cells, adrenals, liver, platelets, brain, and mesangial cells; V 2 receptor (20) in kidney; and V 3 (or V 1b ) receptor (21) in pituitary, and possibly in kidney. AVP was shown to directly stimulate growth and steroidogenesis in rat, bovine, dog, and frog adrenal cells (22) (23) (24) (25) ; it inhibits steroidogenesis in Leydig cells (26) . AVP also stimulates cortisol secretion from normal human adrenals in vitro (27, 28) i was similar in the adrenal cells of our patient (0.9 nmol/L) compared with glomerulosa-rich cells (1.4 nmol/L) from normal adrenals (28) . Although our RT-PCR assay was not quantitative, there does not seem to be a gross overexpression of the V 1 -AVPR. Direct sequencing of this receptor will be necessary to clarify whether an activating mutation is present. Activating mutations of the TSH receptor in thyroid toxic nodules (30) or the LH receptor in familial male precocious puberty (31) can lead to target tissue hyperplasia and increased function. The diffuse and bilateral hyperplasia in this and other patients with AIMAH (5-7) suggest that the putative mutation must have occurred during early embryogenesis, whereas somatic mutations would be responsible for unique adenomas (8, 9) .
In vitro evidence of ectopic receptors in adrenocortical tumors were described for catecholamines, TSH, LH, HCG, PRL, GH, glucagon, and AVP (7, 32, reviewed in Ref. 33) . Gastric inhibitory polypeptide (GIP)-dependent Cushing's syndrome (5-9) constitutes the first clinically recognized demonstration of the role of abnormal hormone receptors in the pathophysiology of adrenal tumors or hyperplasia. Because the V 1 -AVPR was present in the normal adrenal cortex, the abnormality described here would rather be secondary to the abnormal function of a eutopic receptor-effector system. Recently, the V 3 -AVP receptor was shown to be expressed ectopically in a bronchial carcinoid secreting ACTH (34); in addition, most patients with Cushing's disease (but not normal individuals) secrete ACTH in response to dDAVP, suggesting ectopic V 2 -AVPR or abnormal V 3 -AVPR response in corticotroph adenoma cells (35) . AVP was a logical candidate endogenous modulator of cortisol secretion during postural hypotension in this patient, because exogenous AVP exerted such a potent effect on cortisol production and should increase during orthostatic hypotension (36) . Endogenous AVP was below the limit of detection initially but maintained normal water balance in this patient; thus AVP may have modulated steroidogenesis via hyperresponsive V 1 -AVPR. Glucocorticoid receptors in the paraventricular nuclei (37) are modulated by osmolarity and mediate cortisol negative feedback on vasopressin transcription; this may explain why AVP levels were undetectable, despite the orthostatic hypotension before adrenalectomy. The puzzling persistence of relatively suppressed AVP levels after bilateral adrenalectomy raises the possibility that an exaggerated feedback V 1 -AVPR signal may be exerted at the hypothalamic level in this patient; V 1 -AVPR are present in several brain regions, but it is still unknown whether AVP-producing neurons express such receptors and whether AVP synthesis is regulated by its V 1 -AVPR. AVP also has been shown to be produced in normal adrenal medulla and cortex in 
FIG. 5.
In vitro vasoconstrictor responses of small arteries from gluteal fat biopsies to vasopressin. Active wall tension generated by small arteries from the patient with AIMAH (upper panel) and from a control male patient (bottom panel), after incubation with increasing concentrations of AVP; the control was representative of a normal control group in a previously published report (16) . Note the prolonged duration of the vasoconstrictive response in the patient with AIMAH after AVP washout.
humans, as well as in other species (27, 28) , raising the possibility of a paracrine regulatory role of AVP on adrenal steroidogenesis and, possibly, growth in this patient with AIMAH. CRH stimulates AVP release from the adrenal medulla (28) ; CRH stimulated cortisol secretion in vivo in this patient with only minor changes in ACTH levels, but no direct effect of CRH was found in adrenocortical cells in vitro (not shown).
Alternative mediators of cortisol triggered by upright posture included catecholamine surges, with ectopic ␤-adrenergic receptors (32) ; no response was found to insulin-induced hypoglycemia or isoproterenol administration in vivo or in vitro. Another potential modulator was angiotensin II, but renin was suppressed and infusion of angiotensin II failed to elicit a cortisol production in vivo. The decreased basal levels of aldosterone and renin could have resulted from AVP-dependent regulation of inappropriate cortisol and aldosterone production. ETs have also been shown to be produced in adrenal glands, where their receptors are present (38) ; ETs stimulate cortisol and aldosterone production (38, 39) . The lack of increase of ET-1 levels while cortisol increased during upright posture suggests that ET-1 was not an important regulator of steroidogenesis in vivo in this patient.
The pathophysiology of the orthostatic hypotension in this patient is unclear. Cushing's syndrome often is accompanied by blood volume expansion and high blood pressure (1); thus, the decreased blood volume and delayed postural hypotension of this patient certainly is most atypical. AVP normally exerts a vasoconstrictor effect on vascular smooth muscle; this patient's small artery maximal constrictor response to AVP was not increased, but an intriguing prolongation of the constrictor effect of AVP was noted. This may suggest that an abnormal response of V 1 -AVPR-effector system was present not only in the adrenals, but also in vascular and other tissues. Paradoxical vasodilator effects of high concentrations of vasopressin in certain vascular beds have been described previously (40, 41) ; however, there was no evidence in vivo of such paradoxical effects of vasopressin in this patient.
ET-1 is a vasoconstrictor peptide synthesized by endothelial cells but also by neurons in the paraventricular and supraoptic nuclear neurons of the hypothalamus, with terminals in posterior pituitary (42) . Plasma levels of ET-1 increase concomitantly with vasopressin during upright posture in normal individuals but not in patients with autonomic failure or central diabetes insipidus (43) ; this suggests that the source of ET-1 during postural changes is from the posterior pituitary, rather than from peripheral endothelial cells. The failure to increase ET levels in this patient during orthostatic hypotension clearly is not related to autonomic failure. The persistence of a lack of response of ET to upright posture, several months after the correction of hypercorticism, raises the possibility that an exaggerated V 1 -AVPR signal may alter the vasopressin and ET response at the hypothalamic level. A combined contribution of the relatively deficient vasoconstrictor systems AVP, ET, and reninangiotensin II to the pathophysiology of orthostatic hypotension in this patient certainly is another possibility.
In conclusion, it is proposed that a generalized hyperresponsiveness of the V 1 -AVPR-effector system underlied the macronodular adrenal hyperplasia, hypercorticism and also may be implicated in the orthostatic hypotension in this patient; this abnormality would lead to AVP-modulated secretion of cortisol and aldosterone and to feedback suppression of the CRH-ACTH-adrenal and renin-angiotensin axis, as well as to decreased hypothalamic AVP and ET release. In addition, abnormal vascular responses of the V 1 -AVPR-effector system may underlie a redistribution of blood volumes in the upright posture, leading to the delayed-onset orthostatic hypotension. Futher studies to characterize this patient's AVP receptor-effector systems at the molecular level will be necessary to clarify this hypothesis. This study lends support to our broader hypothesis that AIMAH or adrenocortical tumors (including cortisol, aldosterone, androgens, or estrogens secreting) may be secondary to either ectopic hormone receptors (such as GIPR, ␤-adrenergic receptors) or any other receptor capable of coupling to G proteins and steroidogenesis, or to abnormalities of eutopic receptors such as those for ACTH, AVP, angiotensin ll, serotonin, ANP, or growth factors. This may eventually lead to pharmacological therapy as an alternative to adrenalectomy; it will be interesting to treat patients such as this one with oral V 1 -AVPR antagonists (44, 45) , when they become available for human use.
